Mangoceuticals Pivots from Men's Health to Advanced Nuclear via Reverse Merger with Nuclea Energy
MGRX has more than doubled off its 52-week low of $0.162 on light trading volume (0.2× avg).
Summary
Mangoceuticals is being acquired by private nuclear startup Nuclea Energy in a reverse merger that will give Nuclea shareholders 96% ownership. The deal includes a $15M PIPE, CEO departure, and governance changes, marking a complete pivot from men's health to advanced nuclear technology.
Updates
· SEC 425 — The merger agreement requires voting support agreements covering at least 9,119,823 shares, about 50.1% of Mango's outstanding stock, from Jacob Cohen and affiliates. The deal is structured in two stages: closing before required approvals, then completion after.
Key Events · M&A and Partnerships · MGRX
-
Reverse Merger with Nuclea Energy
Mangoceuticals has signed a Business Combination Agreement with Nuclea Energy Inc., a private Canadian advanced nuclear technology company. Under the reverse merger, Nuclea shareholders will receive exchangeable shares representing approximately 96% of Mango's fully diluted equity, effectively taking control of the public company.
-
$15M PIPE Financing Condition
Closing is contingent on a private investment in public equity (PIPE) of at least $15 million, which must be funded into escrow and released at closing. This financing is critical for the combined company's operations and Nuclea's planned acquisition of Moltex assets.
-
CEO Departure and Severance Package
Upon closing, CEO Jacob D. Cohen will resign and transition to President under a consulting agreement. He will receive $1.5 million in cash severance, 2 million shares of Mango common stock issued immediately, and a $10 million cashless warrant in Mango & Peaches Corp. upon deal completion.
-
Governance Changes to Facilitate Deal
The Board amended the bylaws to reduce the shareholder meeting quorum from a majority to one-third of voting power, effective immediately. This change likely ensures the company can achieve quorum for the stockholder vote needed to approve the transaction.
Analysis · MGRX · Industrial Applications And Services
In a dramatic strategic shift, Mangoceuticals—a micro-cap men's health company trading at $0.54 with a going concern warning—is set to acquire private nuclear technology developer Nuclea Energy through a reverse merger. The deal hands Nuclea shareholders roughly 96% ownership of the combined entity, effectively giving them control of Mango's Nasdaq listing. Closing hinges on a $15 million PIPE financing, a lifeline given Mango's cash crunch. As part of the transition, CEO Jacob Cohen will step down, receiving a $1.5 million cash severance, 2 million shares, and a $10 million warrant in a subsidiary. To smooth the approval process, the board also lowered the shareholder meeting quorum requirement. This transaction marks a complete overhaul of the company's business and risk profile—from consumer health to pre-revenue nuclear technology—coming just two months after Mango reiterated its going concern warning.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 40.5% of the 331 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MGRX was trading at $0.54 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $9.5M. The 52-week trading range was $0.16 to $2.75. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.